IONIS PHARMACEUTICALS INC
sefaxersen
IgA nephropathy
Date
TBD
Phase 3 readout · Date TBD estimated
What's at stake
Phase 3 trial results for sefaxersen in IgA nephropathy are due Date TBD. A clean hit validates the program; a miss can gap the stock down hard.
Primary source
· SEC 8-K
verified 12h ago
“Additional Phase 3 readouts from partnered programs: o Results from IMAGINATION study of sefaxersen for IgA nephropathy (IgAN) (Roche)”